Tags : Salix Pharmaceuticals


RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106

Shots: RedHill regains exclusive WW rights for RHB-106 signed in 2014, encapsulated formulation for bowel preparation In 2014, RedHill signed a license agreement with Salix to commercialize RHB-106 in specific territories. RedHill received $7M up front and up to $5M in milestones, plus royalties RHB-106 is a flavorless, odorless, solid oral encapsulated formulation P-IIa candidate […]Read More